$HALO News

Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today

Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E

Implied Volatility Surging for Halozyme Therapeutics Stock Options

Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns

Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions

Halozyme Therapeutics: Royalty King

3 Growth Stocks Set to Flourish

Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)

HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook

Halozyme Therapeutics Earnings: What To Look For From HALO

Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK

Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley

Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $93

Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...

Halozyme Therapeutics Q1 Earnings Call Highlights

Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript

Halozyme Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

Halozyme Therapeutics (NASDAQ:HALO) Surges After Q1 Beat, Launches $1 Billion Buyback